Organon &

Organon & Forward P/E

The Forward P/E Ratio of Organon & (OGN) as of Oct 24, 2026 is 10.27. In the previous year, Forward P/E Ratio was 2.22 — a change of 362.03% (higher).

Forward P/E

10.27

YoY

362.03%

Last updated:

Forward P/E Ratio of Organon & is 2025 10.27 . Forward P/E Ratio of Organon & was 2024 2.22 . It decreases by 362.03% higher compared to the previous year.

The Organon & Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
0.89 USD
Jan 1, 2019
0.60 USD
Jan 1, 2020
0.89 USD
Jan 1, 2021
1.42 USD
Jan 1, 2022
2.10 USD
Jan 1, 2023
1.88 USD
Jan 1, 2024
2.22 USD
Jan 1, 2025
10.27 USD
The Organon & Forward P/E history
YEARForward P/EYoY
10.27+362.03%
2.22+18.40%
1.88-10.36%
2.10+47.33%
1.42+59.88%
0.89+48.98%
0.60-33.10%
0.89-16.35%
1.07—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers. Organon & is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Organon & stock

Forward P/E Ratio of Organon & is 10.27 in 2025.

Forward P/E Ratio of Organon & changed from 2.22 to 10.27, representing a 362.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Organon & since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Organon & with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Organon &

All Key Metrics — Organon &